Prosecution Insights
Last updated: August 18, 2026

Examiner: KAPUSHOC, STEPHEN THOMAS

Tech Center 1600 • Art Units: 1634 1683 1699

This examiner grants 47% of resolved cases

Performance Statistics

46.7%
Allow Rate
-13.3% vs TC avg
808
Total Applications
+53.2%
Interview Lift
1377
Avg Prosecution Days
Based on 737 resolved cases, 2023–2026

Rejection Statute Breakdown

23.4%
§101 Eligibility
11.3%
§102 Novelty
22.4%
§103 Obviousness
34.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18362013 SEQUENCE CONVERSION AND SIGNAL AMPLIFIER DNA HAVING ABASIC NUCLEIC ACIDS, AND DETECTION METHODS USING SAME Non-Final OA ABBOTT LABORATORIES
18568042 INTERNAL STANDARD NUCLEIC ACID FOR QUANTIFYING EUKARYOTIC MICROORGANISMS Non-Final OA NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
18582159 Treatment Of Obesity In Subjects Having Variant Nucleic Acid Molecules Encoding Calcitonin Receptor (CALCR) Non-Final OA Regeneron Pharmaceuticals, Inc.
18455954 NUCLEIC ACID DELIVERY SCAFFOLDS Non-Final OA Singular Genomics Systems, Inc.
18034876 USE OF BRAIN ORGANOIDS AND SINGLE CELL GENOMICS TO UNDERSTAND AND TREAT NEURODEVELOPMENTAL AND NEUROPSYCHIATRIC DISORDERS Non-Final OA Massachusetts Institute of Technology
17999137 PERSONALISED RECOMMENDED DAILY INTAKE FOR NUTRIENTS BASED ON INDIVIDUAL GENETIC RISK SCORES Final Rejection SOCIETE DES PRODUITS NESTLE S.A.
18258872 METHODS FOR PERFORMING MULTIPLEXED REAL-TIME PCR WITH THE USE OF LARGE STOKES SHIFT FLUORESCENT DYES Non-Final OA Roche Molecular Systems, Inc.
18291403 PCR KIT-OF-PARTS, METHOD AND SYSTEM Non-Final OA Hewlett-Packard Development Company, L.P.
18403902 MULTI-OMIC ANALYSIS IN MONODISPERSE DROPLETS Non-Final OA ILLUMINA, INC.
18270684 HIGH-SPATIAL-RESOLUTION EPIGENOMIC PROFILING Non-Final OA YALE UNIVERSITY
18168955 METHODS OF DETERMINING COVID-19 MORTALITY RISK Non-Final OA WASHINGTON UNIVERSITY
18340581 COMPOSITIONS AND METHODS FOR HIGHLY SENSITIVE DETECTION OF TARGET SEQUENCES IN MULTIPLEX REACTIONS Non-Final OA Life Technologies Corporation
17787433 NOVEL DRUGGABLE TARGETS FOR THE TREATMENT OF INFLAMMATORY DISEASES SUCH AS SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND METHODS FOR DIAGNOSIS AND TREATMENT USING THE SAME Final Rejection THE CHILDREN'S HOSPITAL OF PHILADELPHIA
17906123 THERAPEUTIC METHODS FOR THE TREATMENT OF SUBJECTS WITH RISK ALELLES IN IL33 Final Rejection MedImmune Limited
18572107 UNIT-DNA COMPOSITION FOR SPATIAL BARCODING AND SEQUENCING Non-Final OA Miltenyi Biotec B.V. & Co. KG
18368415 METHODS AND COMPOSITIONS FOR SINGLE-STRANDED NUCLEIC ACID LADDERS BY GUIDED CLEAVAGE Non-Final OA Revvity Health Sciences, Inc.
17905021 METHODS AND KITS FOR TREATING OR DIAGNOSING CANNABINOID HYPEREMESIS SYNDROME Non-Final OA CReDO Science, LLC

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month